Actively Recruiting
Time Required to Dissolve Urate Deposits
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2026-02-19
250
Participants Needed
1
Research Sites
417 weeks
Total Duration
On this page
Sponsors
A
Assistance Publique - Hôpitaux de Paris
Lead Sponsor
I
Institut National de la Santé Et de la Recherche Médicale, France
Collaborating Sponsor
AI-Summary
What this Trial Is About
Gout is characterized by episodes of acute arthritis of the lower limbs due to intermittent activation of innate immunity in the joints where urate crystals have formed. These crystals occur when serum urate (SUA) levels have been above 70 mg/L for many years. They can be dissolved by lowering SUA levels to at least 60 mg/L (treat-to-target - T2T - strategy). Once the crystals are dissolved, patients are no longer symptomatic and are considered to be in remission (treat-to-dissolve - T2D - strategy). The presence of crystals and their dissolution during treatment can be monitored by repeated ultrasound (US) scans of the feet and knees. The time required for complete dissolution varies from patient to patient. ReViGore40 is a cohort designed to i) determine the time to complete dissolution of urate deposits in joints when SUA levels are maintained below 40 mg/L, ii) determine the factors (clinical, biological, genetic) associated with the time required for complete dissolution of urate deposits within joints.
CONDITIONS
Official Title
Time Required to Dissolve Urate Deposits
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age over 18 years
- Diagnosis of gout according to the ACR/Eular 2015 criteria
- Serum urate (SUA) levels greater than 60 mg/L
- Ultrasound score of 2 or higher out of 24 in feet or knees
- Dated and voluntarily signed informed consent
You will not qualify if you...
- Currently receiving urate-lowering therapy
- Severe and uncontrolled diseases such as cancer, cardiovascular, or neurovegetative diseases
- Pregnant or breastfeeding women
- No affiliation with the French National Social Security System
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
APHP, Lariboisière Hospital, Rheumatology departement
Paris, France, 75010
Actively Recruiting
Research Team
P
Pascal RICHETTE, PR
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here